Lack of standard guidelines for optimal needle insertion during high-dose-rate (HDR) intracavitary-interstitial (IC-IS) brachytherapy of the cervix means a sophisticated and technical skillset of inserting needles next to IC applicators must be developed to enhance plan quality. This study sought to evaluate the performance of two separate direction modulated brachytherapy (DMBT) tandem applicators used in conjunction with one set of novel DMBT ovoids, uniquely designed to effectively obviate the need for IS needles. A cohort of 32 retrospective clinical HDR brachytherapy plans, from three institutions, were re-planned with Varian's BrachyVision® (v16.1) treatment planning system (BV-TPS), using the latest VEGO® inverse optimization algorithm, with dose heterogeneity accounted for through the AcurosBV®. All plans consisted of IC-IS cases, with a range of 2-4 freehand-loaded needles, with an average prescription dose of 709±53 cGy, and with an average high-risk clinical target volume (HRCTV) of 36.73±17.15 [range 9.8-69.6] cm3. Two DMBT tandem models of 5.4-mm and 8.0-mm thicknesses along with a novel DMBT ovoids design, introduced for the first time, with 9 equi-angled grooves and 10-mm-diameter thickness. During re-planning, the conventional tandems, ovoids/rings, and all of the needles were replaced by one of the two DMBT tandem models and a set of DMBT ovoids. A two-step inverse optimization process was performed to achieve the lowest possible OAR D2cc doses while 1) keeping equivalent target coverage (ΔHRCTV-D90 to within ±0.5%) and 2) maintaining the general pear-shape dose distribution used by the original plans. For all plans, this process was repeated using each of the two DMBT tandem-and-ovoids combinations for a total re-planning of (32×2 =) 64 cases. On average, -47.15±29.61 (-40.40±34.90) cGy, -42.98±26.58 (-41.70±27.40) cGy, and -40.47±25.05 (-32.55±25.30) cGy reductions in D2cc across bladder, rectum, and sigmoid, respectively, were achieved for the 8-mm (5.4-mm) DMBT tandem-and-ovoids combinations while the average ΔHRCTV-D90 was +4.3±2.9 cGy (+0.5%±0.4%). Additionally, D2cc reductions in terms of EQD2 [Gy] were calculated and showed significant reductions of -4.05±2.47 (-3.37±2.83) Gy, -2.71±1.79 (-2.59±1.74) Gy, and -3.27±1.96 (-2.65±2.06) Gy for bladder, rectum, and sigmoid, respectively with an average net increase in total dwell times of 241.0±87.6 seconds at the luxury of avoiding IS needle insertions. It is clinically feasible to obviate the need for IS needles by incorporating the DMBT tandem-and-ovoids while producing lower OAR D2cc doses and maintaining equivalent target coverage.
Read full abstract